Application | Comment | Organism |
---|---|---|
medicine | a DPP-IV inhibitor (3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate) in combination with glybenclamide or nateglinide may be a promising option for the treatment of type 2 diabetes, and particularly, for controlling postprandial hyperglycemia in the clinic | Mus musculus |
medicine | a DPP-IV inhibitor (3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate) in combination with glybenclamide or nateglinide may be a promising option for the treatment of type 2 diabetes, and particularly, for controlling postprandial hyperglycemia in the clinic | Rattus norvegicus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate | i.e. E3024, selective, and competitive | Mus musculus | |
3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate | i.e. E3024, selective, and competitive | Rattus norvegicus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
male C57BL/6NCrj mice | - |
Rattus norvegicus | - |
Wistar rats | - |
Synonyms | Comment | Organism |
---|---|---|
dipeptidyl peptidase IV | - |
Mus musculus |
dipeptidyl peptidase IV | - |
Rattus norvegicus |
DPP-IV | - |
Mus musculus |
DPP-IV | - |
Rattus norvegicus |